Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Completion of Rolling BLA Submission for ELZONRIS™ (tagraxofusp; SL-401) for the Treatment of BPDCN

NEW YORK, June 25, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that it has...
June 18, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Positive Clinical Data from ELZONRISTM (tagraxofusp; SL-401) Trials in BPDCN, CMML and MF Delivered at the EHA Congress

NEW YORK, June 18, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
June 15, 2018 08:15 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Presentation of ELZONRIS™ (tagraxofusp; SL-401) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

NEW YORK, June 15, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
June 14, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three ELZONRIS™ (tagraxofusp; SL-401) Clinical Presentations, Including an Oral Presentation, at the EHA Congress

NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced that ELZONRISTM...
June 05, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO

NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
May 18, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three SL-401 Clinical Presentations, Including an Oral Presentation, at the Upcoming EHA Congress

NEW YORK, May 18, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that SL-401...
May 17, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting

NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that clinical...
May 09, 2018 16:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports First Quarter 2018 Financial Results

NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial...
April 26, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Clinical Presentations of SL-801 and SL-701 at the Upcoming ASCO Annual Meeting

NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
April 16, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline

NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced expansion...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right